Life Saving Technology for Thoracic Trauma Treatment and Post Operative Drainagebroad
C-LANT Drainage Port · Horizon Europe grant · 2023-03-01–2025-11-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Thoracic trauma is the 1st cause of accidental death globally, with a mortality rate of 60% in polytraumatic patients. The time of treatment is crucial. 80% of patients can be potentially saved if they are treated in 1h. However, current solutions to treat it are limited and static for the last 30-50 years. C-LANT is a unique self-fixating, a-traumatic and multifunctional device tackling this unmet need by offering a safe, fast, easy to use, multifunctional and cost-effective tool for treating any type of chest trauma or postoperative drainage following major thoracic and abdominal procedures. It reduces the procedure time by 20x and saves up to €2.6Bn associated with additional tube replacement (EU).With the EIC support Vigor aims to accelerate the clinical validation and scaling-up of C-LANT, providing a global impact to healthcare systems, clinicians, and patients. C-LANT will be part of the growing Emergency Medical Devices and the Surgical Drains markets (total valued >40B -2030)
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| VIGOR MEDICAL TECHNOLOGIES LTD | IL | coordinator | €2,499,875 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.